Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
Portfolio Pulse from
Sagimet Biosciences has received clearance for its IND application for TVB-3567, a FASN inhibitor aimed at treating acne. The company plans to initiate a Phase 1 trial in 2025.
March 11, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sagimet Biosciences has received IND clearance for its FASN inhibitor TVB-3567, targeting acne treatment. This regulatory milestone paves the way for a Phase 1 trial in 2025.
The IND clearance is a significant regulatory milestone for Sagimet Biosciences, allowing them to proceed with clinical trials. This development could positively impact SGMT's stock as it represents progress in their product pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100